14. Biogen, Inc. (BIIB-US)

Biogen, Inc., headquartered in Cambridge, Mass., develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. On December 31, 2019, Biogen’s stock sold at $296.73 a share, but rose to $316.38 a share on March 31, 2020, earning a 6.6% return on investment with no current dividend yield.